Fastest Revenue Growth
Companies growing revenue at 20%+ annually. High-growth businesses that are scaling fast. $1B+ market cap.
200 stocks
Updated Jun 24, 2026
$13.14T
Total Market Cap
—
Avg P/E Ratio
$60.54
Avg Share Price
+0.00%
Avg Daily Change
Revenue growth is the most fundamental measure of a company's business expansion. This list features companies growing annual revenue at 20% or more — a pace that far exceeds the average S&P 500 company and signals businesses that are capturing market share, entering new markets, or riding powerful industry tailwinds.
High revenue growth drives stock prices because it represents expanding demand for a company's products and services. Investors pay premium valuations for fast growers because today's revenue growth becomes tomorrow's earnings growth. Companies like Nvidia, CrowdStrike, and Palantir have delivered exceptional stock returns fueled by rapid top-line expansion in high-demand sectors.
This list screens for companies with market caps above $1 billion and annual revenue growth exceeding 20%. It includes the growth rate, total revenue, profit margin, and market cap — key metrics for evaluating whether growth is translating into shareholder value. Financial data is updated weekly from reported earnings.
| # | Symbol | Name | Price | Rev Growth | Revenue | Margin | Market Cap |
|---|---|---|---|---|---|---|---|
| 1 | NIQ | Niq Global Intelligence Plc | $8.09 | 715.48% | 4.64B | -8.42% | 2.44B |
| 2 | IBRX | Immunitybio Inc | $7.32 | 678.62% | 129.03M | -310.18% | 7.71B |
| 3 | RZLV | Rezolve Ai Plc | $2.66 | 640.71% | 71.75M | -216.69% | 1.08B |
| 4 | CRWV | Coreweave Inc-Cl A | $105.72 | 586.92% | 6.44B | -22.74% | 64.35B |
| 5 | AMLX | Amylyx Pharmaceuticals Inc | $16.52 | 574.28% | 140.51M | -345.36% | 1.74B |
| 6 | EAT | Brinker International Inc | $164.25 | 550.26% | 5.01B | 7.12% | 7.07B |
| 7 | TGTX | Tg Therapeutics Inc | $53.94 | 504.86% | 584.49M | 72.56% | 8.15B |
| 8 | QXO | Qxo Inc | $16.22 | 433.80% | 8.10B | -4.08% | 12.88B |
| 9 | BAM | Brookfield Asset Mgmt-A | $46.96 | 406.83% | 4.70B | 51.59% | 75.75B |
| 10 | ARQT | Arcutis Biotherapeutics Inc | $26.27 | 367.11% | 369.72M | -4.29% | 3.28B |
| 11 | CAPR | Capricor Therapeutics Inc | $29.88 | 352.73% | 30.52M | -181.71% | 1.64B |
| 12 | CIFR | Cipher Mining Inc | $27.64 | 319.20% | 240.03M | -367.17% | 11.94B |
| 13 | SLNO | Soleno Therapeutics Inc | $53.01 | 298.89% | 189.44M | 10.97% | 2.76B |
| 14 | VRDN | Viridian Therapeutics Inc | $17.28 | 242.07% | 92.26M | -483.57% | 1.84B |
| 15 | NBIS | Nebius Group Nv | $275.25 | 239.83% | 538.31M | 15.57% | 72.15B |
| 16 | ONDS | Ondas Inc | $8.53 | 187.72% | 118.33M | -260.23% | 4.79B |
| 17 | ANAB | Anaptysbio Inc | $62.23 | 183.56% | 244.72M | -5.64% | 1.67B |
| 18 | IESC | Ies Holdings Inc | $710.54 | 180.45% | 3.33B | 9.08% | 14.19B |
| 19 | CGON | Cg Oncology Inc | $65.73 | 176.56% | 4.61M | -3,985.02% | 5.39B |
| 20 | ATAI | Ataibeckley Inc | $4.20 | 160.99% | 6.70M | -16,142.02% | 1.49B |
| 21 | TARS | Tarsus Pharmaceuticals Inc | $63.39 | 159.53% | 464.75M | -14.72% | 2.72B |
| 22 | APLD | Applied Digital Corp | $45.27 | 156.45% | 204.81M | -160.25% | 13.31B |
| 23 | ASST | Strive Inc-A | $13.95 | 155.67% | 10.33M | -7,334.98% | 1.18B |
| 24 | AMPX | Amprius Technologies Inc | $14.12 | 154.87% | 82.25M | -60.30% | 2.29B |
| 25 | AKTS | Aktis Oncology Inc | $26.04 | 147.45% | 7.08M | -980.93% | 1.33B |
| 26 | STOK | Stoke Therapeutics Inc | $31.00 | 145.85% | 201.63M | -3.73% | 1.93B |
| 27 | BMNR | Bitmine Immersion Technologi | $15.13 | 142.45% | 141.60M | 5,719.06% | 9.19B |
| 28 | APLS | Apellis Pharmaceuticals Inc | $41.03 | 137.00% | 1.02B | 2.23% | 5.25B |
| 29 | AXSM | Axsome Therapeutics Inc | $241.97 | 133.68% | 660.48M | -28.69% | 12.89B |
| 30 | PTCT | Ptc Therapeutics Inc | $82.13 | 128.31% | 1.63B | 39.44% | 6.55B |
| 31 | WVE | Wave Life Sciences Ltd | $6.16 | 127.06% | 49.05M | -478.33% | 1.19B |
| 32 | IONQ | Ionq Inc | $57.85 | 126.90% | 173.12M | -392.55% | 21.11B |
| 33 | WULF | Terawulf Inc | $28.78 | 123.79% | 209.96M | -392.64% | 14.36B |
| 34 | RLAY | Relay Therapeutics Inc | $15.88 | 123.25% | 19.88M | -1,800.58% | 3.46B |
| 35 | ALAB | Astera Labs Inc | $397.02 | 120.18% | 813.86M | 25.70% | 71.49B |
| 36 | LQDA | Liquidia Corp | $74.04 | 114.96% | 163.60M | -43.53% | 6.32B |
| 37 | IREN | Iren Ltd | $54.72 | 103.98% | 800.90M | 17.35% | 21.40B |
| 38 | RYTM | Rhythm Pharmaceuticals Inc | $106.19 | 100.22% | 200.29M | -103.57% | 6.64B |
| 39 | NVDA | NVIDIA Corp | $200.04 | 100.05% | 213.17B | 55.60% | 5.10T |
| 40 | ARDX | Ardelyx Inc | $6.36 | 98.40% | 216.86M | -14.36% | 1.49B |
| 41 | ARDX | Ardelyx Inc | $6.36 | 98.40% | 430.26M | -15.12% | 1.49B |
| 42 | MARA | Mara Holdings Inc | $14.70 | 97.47% | 973.76M | -144.58% | 5.42B |
| 43 | MARA | Mara Holdings Inc | $14.70 | 97.47% | 493.12M | -137.35% | 5.42B |
| 44 | AVDL | Avadel Pharmaceuticals | $21.64 | 96.37% | 174.47M | -28.87% | 2.12B |
| 45 | AVDL | Avadel Pharmaceuticals | $21.64 | 96.37% | 88.85M | -27.43% | 2.12B |
| 46 | SATS | Echostar Corp-A | $103.92 | 95.83% | 15.12B | -96.62% | 31.64B |
| 47 | SATS | Echostar Corp-A | $103.92 | 95.83% | 7.72B | -91.79% | 31.64B |
| 48 | CRDO | Credo Technology Group Holdi | $272.01 | 93.53% | 1.32B | 35.37% | 50.69B |
| 49 | CRDO | Credo Technology Group Holdi | $272.01 | 93.53% | 683.44M | 33.60% | 50.69B |
| 50 | ALVO | Alvotech Sa | $3.73 | 90.62% | 357.02M | 4.50% | 1.31B |
| 51 | ALVO | Alvotech Sa | $3.73 | 90.62% | 680.55M | 4.74% | 1.31B |
| 52 | MIRM | Mirum Pharmaceuticals Inc | $111.07 | 89.13% | 334.85M | -4.26% | 6.53B |
| 53 | MIRM | Mirum Pharmaceuticals Inc | $111.07 | 89.13% | 633.30M | -4.48% | 6.53B |
| 54 | TMDX | Transmedics Group Inc | $73.83 | 86.42% | 276.89M | 29.86% | 2.72B |
| 55 | TMDX | Transmedics Group Inc | $73.83 | 86.42% | 516.18M | 31.43% | 2.72B |
| 56 | VFS | Vinfast Auto Ltd | $3.16 | 86.38% | 90.19T | -110.21% | 7.11B |
| 57 | VFS | Vinfast Auto Ltd | $3.16 | 86.38% | 48.39T | -104.70% | 7.11B |
| 58 | BBIO | Bridgebio Pharma Inc | $68.63 | 86.30% | 513.43M | -144.39% | 12.98B |
| 59 | BBIO | Bridgebio Pharma Inc | $68.63 | 86.30% | 275.59M | -137.17% | 12.98B |
| 60 | EOSE | Eos Energy Enterprises Inc | $6.49 | 85.40% | 148.64M | -849.06% | 2.60B |
| 61 | EOSE | Eos Energy Enterprises Inc | $6.49 | 85.40% | 80.17M | -806.61% | 2.60B |
| 62 | CLSK | Cleanspark Inc | $17.24 | 79.95% | 647.38M | 47.56% | 4.42B |
| 63 | CLSK | Cleanspark Inc | $17.24 | 79.95% | 359.75M | 45.18% | 4.42B |
| 64 | BMNR | Bitmine Immersion Technologi | $15.13 | 79.39% | 16.68M | -94.49% | 9.19B |
| 65 | ORLA | Orla Mining Ltd | $9.77 | 76.26% | 836.99M | 9.60% | 5.09B |
| 66 | ORLA | Orla Mining Ltd | $9.77 | 76.26% | 1.48B | 10.10% | 5.09B |
| 67 | SOUN | Soundhound Ai Inc-A | $6.44 | 75.73% | 180.34M | -8.29% | 3.08B |
| 68 | SOUN | Soundhound Ai Inc-A | $6.44 | 75.73% | 102.62M | -7.88% | 3.08B |
| 69 | UUUU | Energy Fuels Inc | $15.47 | 73.97% | 42.25M | -123.41% | 4.15B |
| 70 | UUUU | Energy Fuels Inc | $15.47 | 73.97% | 73.50M | -129.90% | 4.15B |
| 71 | ENVX | Enovix Corp | $6.74 | 72.49% | 19.72M | -467.94% | 1.54B |
| 72 | ENVX | Enovix Corp | $6.74 | 72.49% | 34.02M | -492.57% | 1.54B |
| 73 | ASTS | Ast Spacemobile Inc | $72.87 | 72.44% | 107.51M | -482.16% | 31.31B |
| 74 | ASTS | Ast Spacemobile Inc | $72.87 | 72.44% | 62.35M | -458.05% | 31.31B |
| 75 | FLOC | Flowco Holdings Inc-Cl A | $21.91 | 72.27% | 447.69M | 5.18% | 2.05B |
| 76 | FLOC | Flowco Holdings Inc-Cl A | $21.91 | 72.27% | 771.24M | 5.45% | 2.05B |
| 77 | MGTX | Meiragtx Holdings Plc | $11.59 | 72.27% | 96.44M | -140.31% | 1.05B |
| 78 | MGTX | Meiragtx Holdings Plc | $11.59 | 72.27% | 55.98M | -133.29% | 1.05B |
| 79 | QUBT | Quantum Computing Inc | $10.76 | 69.52% | 591.1K | -2,601.21% | 2.43B |
| 80 | QUBT | Quantum Computing Inc | $10.76 | 69.52% | 1.00M | -2,738.12% | 2.43B |
| 81 | NVDA | NVIDIA Corp | $200.04 | 69.25% | 75.57B | 53.06% | 5.10T |
| 82 | SLDE | Slide Insurance Holdings Inc | $17.11 | 68.31% | 594.42M | 36.49% | 1.90B |
| 83 | SLDE | Slide Insurance Holdings Inc | $17.11 | 68.31% | 1.00B | 38.41% | 1.90B |
| 84 | XZO | Exzeo Group Inc | $13.27 | 68.16% | 147.33M | 36.23% | 1.21B |
| 85 | XZO | Exzeo Group Inc | $13.27 | 68.16% | 247.75M | 38.14% | 1.21B |
| 86 | ELE | Elemental Royalty Corp | $15.71 | 65.44% | 129.77M | 4.06% | 1.44B |
| 87 | ELE | Elemental Royalty Corp | $15.71 | 65.44% | 78.44M | 3.86% | 1.44B |
| 88 | HIMS | Hims & Hers Health Inc | $32.96 | 64.55% | 2.10B | 5.47% | 8.21B |
| 89 | HIMS | Hims & Hers Health Inc | $32.96 | 64.55% | 1.28B | 5.20% | 8.21B |
| 90 | EVRG | Evergy Inc | $84.84 | 63.03% | 4.61B | 12.04% | 19.02B |
| 91 | EVRG | Evergy Inc | $84.84 | 63.03% | 2.83B | 11.44% | 19.02B |
| 92 | AEVA | Aeva Technologies Inc | $24.39 | 62.77% | 19.98M | -804.40% | 1.54B |
| 93 | AEVA | Aeva Technologies Inc | $24.39 | 62.77% | 12.28M | -764.18% | 1.54B |
| 94 | IDYA | Ideaya Biosciences Inc | $31.23 | 62.54% | 235.02M | -51.99% | 2.97B |
| 95 | IDYA | Ideaya Biosciences Inc | $31.23 | 62.54% | 144.59M | -49.39% | 2.97B |
| 96 | SMCI | Super Micro Computer Inc | $33.32 | 61.71% | 22.62B | 4.77% | 19.83B |
| 97 | SMCI | Super Micro Computer Inc | $33.32 | 61.71% | 13.99B | 4.53% | 19.83B |
| 98 | MAAS | Maase Inc-A | $18.90 | 60.57% | 57.73B | -25.08% | 8.36B |
| 99 | MAAS | Maase Inc-A | $18.90 | 60.57% | 35.96B | -23.83% | 8.36B |
| 100 | AKTS | Aktis Oncology Inc | $26.04 | 60.53% | 9.1K | -582.64% | 1.33B |
Frequently Asked Questions
What is revenue growth?
Revenue growth measures the percentage increase in a company's total sales compared to a prior period, typically year-over-year. A company with $1 billion in revenue last year and $1.3 billion this year has 30% revenue growth. It is the most fundamental growth metric because it reflects actual demand for the company's products and services before any expense adjustments. Revenue growth above 20% is considered rapid for companies above $1 billion in market cap.
Why is revenue growth important for stocks?
Revenue growth is the primary driver of long-term stock price appreciation. A company cannot sustainably grow earnings without growing revenue (cost-cutting has limits). Studies show that stocks with the highest revenue growth rates significantly outperform the market over multi-year periods. Revenue growth also attracts institutional investors and analyst upgrades, which increase buying pressure. Wall Street values top-line growth highly because it demonstrates expanding market opportunity.
What is a good revenue growth rate?
A "good" growth rate depends on company size and industry. For large-cap companies ($10B+), 10-15% annual revenue growth is strong. For mid-caps, 15-25% is strong. High-growth companies in technology and healthcare may sustain 30-50%+ growth for several years. The S&P 500 average revenue growth is typically 3-5% annually. Growth rates above 20% for companies over $1 billion in market cap — the threshold for this list — place companies in the top tier of growers.
Is revenue growth better than earnings growth?
Both matter, but revenue growth is considered a higher-quality signal. Revenue growth shows genuine business expansion, while earnings growth can be manufactured through cost-cutting, share buybacks, or accounting adjustments. Ideally, a company shows both — revenue growth demonstrates demand, and improving margins show that growth is becoming profitable. Companies with revenue growth but declining margins may be "buying" growth through unsustainable spending.
What sectors have the fastest revenue growth?
Technology, healthcare, and energy frequently lead in revenue growth. AI and cloud computing companies have posted exceptional growth rates as enterprises adopt new technologies. Biotech companies can see explosive revenue growth when new drugs launch. Energy companies sometimes show high growth rates during commodity price surges. Consumer discretionary and fintech companies also appear frequently among the fastest growers.
Can high revenue growth stocks be risky?
Yes. High-growth stocks often trade at elevated valuations (high P/E or P/S ratios), making them vulnerable to sharp corrections if growth slows. Many high-growth companies are not yet profitable, relying on investor patience and continued capital infusion. Growth deceleration — when a company is still growing but at a slower rate — can trigger significant selloffs. Risk management through position sizing and diversification is particularly important with high-growth stocks.
What is the Rule of 40?
The Rule of 40 is a benchmark for evaluating software and SaaS companies. It states that a company's revenue growth rate plus profit margin should equal or exceed 40%. For example, a company growing at 30% with a 10% margin (30 + 10 = 40) meets the threshold. This framework acknowledges that high-growth companies may sacrifice margins to fuel expansion, while slower growers should compensate with higher profitability. Companies exceeding the Rule of 40 are generally considered high quality.
How to find revenue growth leaders?
This list screens for the fastest revenue growers automatically. For independent research, check quarterly earnings reports for year-over-year revenue growth, SEC filings for annual comparisons, and analyst estimates for projected future growth. Financial platforms display revenue growth in company fundamentals sections. Key factors to evaluate include whether growth is organic (from existing operations) versus acquired, whether it is accelerating or decelerating, and whether the total addressable market supports continued expansion.
More Stock Lists
★
Highest Profit Margins
Cash machines: companies turning over 25% of revenue into net profit. A sign of pricing power, brand moats, and operational efficiency.
→
⬆
Cash Flow Kings
Companies printing the most free cash flow. FCF funds buybacks, dividends, and M&A without taking on debt. $1B+ market cap.
→
✓
Wall Street Strong Buys
The Street's top picks: stocks with a unanimous or near-unanimous Strong Buy consensus from at least 5 analysts. $1B+ companies.
→
○
Mid-Cap Stocks
The growth engine of the market: companies valued between $2B and $10B. Often acquisition targets with room to run.
→
↑
Near 52-Week High
Stocks within 10% of their annual high. Momentum plays that are outperforming the broader market. $1B+ companies only.
→
▲
Highest Analyst Upside
Stocks with the widest gap between current price and Wall Street's average target. Only includes companies valued over $1B with at least 5 analysts and a buy or hold rating.
→